Onset and Duration of Action of Sildenafil for the Treatment of Erectile Dysfunction
Overview
Affiliations
Aims: To determine the onset and duration of action of sildenafil in patients with erectile dysfunction (ED).
Methods: Two randomised, double-blind, placebo-controlled, two-way crossover studies were conducted in men with ED of no known organic cause. Study I: The time to onset of erections after sildenafil (50 mg) or placebo dosing following visual sexual stimulation (VSS) was assessed in 17 patients. Patients not achieving >60% penile rigidity by 70 min postdose as measured by a RigiScan(R) monitoring device were assigned an onset time of 70 min. Study II: The duration of grade 3 (hard enough for penetration) and grade 4 (fully hard) erections, determined by self-assessment during 60 min of VSS starting 2 and 4 h after sildenafil (100 mg) or placebo dosing, was measured in 16 patients.
Results: Study I: The median time (range) to onset of erections was 27 min (in a range of 12--70) after receiving sildenafil 50 mg. In the sildenafil group, 71% of patients experienced onset of erections within 30 min of dosing, and 82% responded within 45 min. Of the patients who achieved >60% penile rigidity after sildenafil, 86% had done so by 30 min after dosing. Study II: When VSS began 2 h postdose, the median duration of grade 3 or 4 erections was 19.5 min (0--55) for sildenafil vs 0 min (0--23) for placebo. When VSS began 4 h postdose, the median duration was 5 min (0--45) for sildenafil compared with 0 min for placebo (0--27).
Conclusions: Sildenafil is an effective oral treatment for ED that produces a penetrative erection as early as 12 min and for most patients, within 30 min after dosing, and a duration of action lasting at least 4 h.
Revolutionising Neurological Therapeutics: Investigating Drug Repurposing Strategies.
Attri M, Raghav A, Sinha J CNS Neurol Disord Drug Targets. 2024; 24(2):115-131.
PMID: 39323347 DOI: 10.2174/0118715273329531240911075309.
Degjoni A, Campolo F, Stefanini L, Venneri M J Thromb Haemost. 2022; 20(11):2465-2474.
PMID: 35950928 PMC: 9805178. DOI: 10.1111/jth.15844.
He Z, Dai L, Zuo Y, Chen Y, Wang H, Zeng H Bioengineered. 2022; 13(6):14667-14680.
PMID: 35880647 PMC: 9342150. DOI: 10.1080/21655979.2022.2100064.
Zakharova A, Efimova S, Ostroumova O Membranes (Basel). 2021; 11(11).
PMID: 34832122 PMC: 8622654. DOI: 10.3390/membranes11110893.
Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang P, Zheng X, Hu X, Yang C, Chen Z, Qian J Drug Des Devel Ther. 2020; 14:5129-5141.
PMID: 33262574 PMC: 7699448. DOI: 10.2147/DDDT.S268796.